0.85
price down icon0.01%   -0.00
after-market Handel nachbörslich: .85
loading
Schlusskurs vom Vortag:
$0.85
Offen:
$0.855
24-Stunden-Volumen:
664.74K
Relative Volume:
6.58
Marktkapitalisierung:
$51.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-112.67M
KGV:
-0.4028
EPS:
-2.11
Netto-Cashflow:
$-79.26M
1W Leistung:
-2.53%
1M Leistung:
-10.54%
6M Leistung:
-16.68%
1J Leistung:
-23.43%
1-Tages-Spanne:
Value
$0.845
$0.8579
1-Wochen-Bereich:
Value
$0.80
$0.92
52-Wochen-Spanne:
Value
$0.69
$1.60

Kronos Bio Inc Stock (KRON) Company Profile

Name
Firmenname
Kronos Bio Inc
Name
Telefon
(650) 781-5200
Name
Adresse
1300 S. EL CAMINO REAL, SAN MATEO
Name
Mitarbeiter
58
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
KRON's Discussions on Twitter

Vergleichen Sie KRON mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
KRON 0.85 51.25M 0 -112.67M -79.26M -2.11
VRTX 467.12 119.83B 10.63B -479.80M -1.35B 13.33
REGN 762.38 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 567.35 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.83 24.08B 3.30B -501.07M 1.03B 11.54

Kronos Bio Inc Stock (KRON) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-09-14 Eingeleitet Berenberg Buy
2021-10-20 Fortgesetzt Cowen Outperform
2021-06-24 Eingeleitet H.C. Wainwright Buy
2020-11-03 Eingeleitet Cowen Outperform
2020-11-03 Eingeleitet Goldman Buy
2020-11-03 Eingeleitet Jefferies Buy
2020-11-03 Eingeleitet Piper Sandler Overweight
Alle ansehen

Kronos Bio Inc Aktie (KRON) Neueste Nachrichten

pulisher
Nov 15, 2024

Kronos Bio Provides Update on Review of Strategic Alternatives - Marketscreener.com

Nov 15, 2024
pulisher
Nov 15, 2024

Kronos Bio shares downgraded to hold by TD Cowen - Investing.com India

Nov 15, 2024
pulisher
Nov 14, 2024

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio Highlights Preclinical Data that Show p300 KAT - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio's KB-7898 Shows 50% Reduction in Inflammation Markers in Preclinical Study | KRON Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio stock takes a hit with piper sandler slashing price target - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos mulls ‘strategic alternatives’ after axing cancer drug development - Pharmaceutical Technology

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio (NASDAQ:KRON) Rating Lowered to "Neutral" at Piper Sandler - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio downgraded by Piper Sandler, TD Cowen (NASDAQ:KRON) - Seeking Alpha

Nov 14, 2024
pulisher
Nov 13, 2024

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

Kronos Bio Reports Third Quarter 2024 Financial Results and - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Kronos Bio Halts Cancer Drug Trial, Explores Strategic Alternatives Amid Safety Concerns | KRON Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 10, 2024

Kronos Bio's Market Cap Drops To US$50m Leaving Insiders With Losses - Simply Wall St

Nov 10, 2024
pulisher
Nov 07, 2024

Kronos Bio faces Nasdaq delisting over share price - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Kronos Bio faces Nasdaq delisting over share price By Investing.com - Investing.com UK

Nov 07, 2024
pulisher
Nov 06, 2024

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma - GlobeNewswire

Nov 06, 2024
pulisher
Nov 05, 2024

Kronos Bio to Present Breakthrough Multiple Myeloma Treatment Data at ASH 2024 | KRON Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

Non-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Nov 04, 2024
pulisher
Nov 04, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Nov 04, 2024
pulisher
Nov 02, 2024

Kronos Bio, Inc. (NASDAQ:KRON) Sees Large Decline in Short Interest - Defense World

Nov 02, 2024
pulisher
Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024
pulisher
Oct 30, 2024

Non-Hodgkin Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 30, 2024
pulisher
Oct 29, 2024

Nio Inc ADR (NIO-N) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

Phillips-Van Heusen Corp (PVH-N) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 25, 2024

After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON) - MSN

Oct 25, 2024
pulisher
Oct 23, 2024

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium - GlobeNewswire

Oct 23, 2024
pulisher
Oct 23, 2024

Taylor Morrison Home Corp (TMHC-N) QuotePress Release - The Globe and Mail

Oct 23, 2024
pulisher
Oct 09, 2024

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times

Oct 09, 2024
pulisher
Oct 09, 2024

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium - GlobeNewswire

Oct 09, 2024
pulisher
Oct 08, 2024

Kronos Bio's (KRON) "Overweight" Rating Reaffirmed at Piper Sandler - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Kronos Bio nominates KAT inhibitor as development candidate for Sjögren’s disease - BioWorld Online

Oct 08, 2024
pulisher
Oct 08, 2024

Piper Sandler maintains Overweight rating on Kronos Bio shares - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Kronos Bio nominates KB-7898 for autoimmune disease treatment - Investing.com

Oct 08, 2024
pulisher
Oct 07, 2024

Kronos Bio nominates KB-7898 for autoimmune disease treatment By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease - The Manila Times

Oct 07, 2024
pulisher
Oct 07, 2024

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease - GlobeNewswire

Oct 07, 2024
pulisher
Oct 01, 2024

Plexium Announces Appointment of Jorge F. DiMartino, M.D., Ph.D. as Chief Medical Officer - PR Newswire

Oct 01, 2024
pulisher
Sep 29, 2024

Kronos Bio, Inc. (NASDAQ:KRON) Position Increased by Forefront Analytics LLC - Defense World

Sep 29, 2024
pulisher
Sep 25, 2024

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - StockTitan

Sep 25, 2024
pulisher
Sep 25, 2024

Kronos Bio to Present Data at ACR Convergence 2024 to - GlobeNewswire

Sep 25, 2024
pulisher
Sep 23, 2024

Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $55.80 - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Avoro Capital Advisors LLC Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Integral Health Asset Management LLC Acquires 45,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

How the (KROS) price action is used to our Advantage - Stock Traders Daily

Sep 23, 2024
pulisher
Sep 23, 2024

How does Keros Therapeutics Inc (KROS) change from a tortoise to a hare? - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Kronos Bio highlights istisociclib data at Ovarian Cancer Research Symposium - TipRanks

Sep 23, 2024
pulisher
Sep 23, 2024

71,428 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Acquired by Tri Locum Partners LP - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Kronos Bio Highlights Data at AACR Ovarian Cancer Research - GlobeNewswire

Sep 23, 2024
pulisher
Sep 23, 2024

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer - StockTitan

Sep 23, 2024

Finanzdaten der Kronos Bio Inc-Aktie (KRON)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$19.00
price up icon 4.27%
$76.98
price up icon 1.23%
$39.53
price up icon 7.03%
$359.21
price down icon 0.88%
$187.76
price down icon 0.58%
$101.83
price up icon 2.00%
Kapitalisierung:     |  Volumen (24h):